安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home - Alkahest
Alkahest, a Grifols subsidiary, is a research and drug discovery company mining the deepest layers of plasma knowledge to inform the development of potential transformative therapies and solutions for patients
- Our Team - Alkahest
Michael Bechauf is the Director of Software and Data Engineering at Alkahest, where he is responsible for providing a scalable data infrastructure and oversees the software engineering processes that ensure robust data analysis and real-world data (RWD) experience for the scientific teams
- Contact - Alkahest
Alkahest, Inc 125 Shoreway Road, Suite D San Carlos, CA 94070 Office: +1 (650) 801-0474 Fax: +1 (650) 801-0480 info@alkahest com
- The Science of Chronokines - Alkahest
At Alkahest, we are decoding the plasma proteome to discover key proteins that increase or decrease with age, which we call chronokines
- Board of Directors - Alkahest
© 2025 Alkahest, Inc All rights reserved All images property of their respective owners Cookies Policy | Privacy Policy | Cookies Settings Therapies Born from
- Careers - Alkahest
If you’d like to help us achieve our vision, we’d love to hear from you Apply for the position that inspires and excites you Take a moment to browse the current openings at Alkahest in San Carlos, Calif , through our parent company Grifols
- Alkahest to Present New Data from Phase 2a Study of AKST4290 in . . .
SAN CARLOS, Calif , July 15, 2019 (GLOBE NEWSWIRE) — Alkahest, Inc , a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study of AKST4290 (originally referred to as ALK4290) in neovascular age-related macular
- Alkahest, Inc. Announces Key Appointment
SAN CARLOS, Calif , — Alkahest Inc (“Alkahest”), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today the appointment of Bruce Morimoto, PhD, as Vice President, Drug Development Operations
|
|
|